Home ›
Leukemia Trials ›
NCT07549464
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.
Trial Details
NCT ID NCT07549464
Phase PHASE1
Sponsor M.D. Anderson Cancer Center
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
Patients need to be adults with R/R AML or MDS/AML per the ICC 2022 or the WHO 2022.4,5 Relapsed or refractory disease following standard treatment: Relapsed: Bone marrow blasts ≥5%, reappearance of blasts in the blood, or development of extramedullary disease following achievement of CR/CRi/MLFS Refractory: Failure to achieve CR/CRi/MLFS following initial treatment, with evidence of persistent leukemia by blood and/or bone marrow evaluation…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →